ImmunoGen (NASDAQ:IMGN)

Ovarian Cancer Study Suffers Big Setback

ImmunoGen Inc. (NASDAQ: IMGN) has released data from its late-stage ovarian cancer study at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain. Specifically, this data comes ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Boeing, Booking, Camping World, Domino’s, iRobot, MetLife, Neogen, Southern Copper, Vertex, Worldpay and More

Stocks were indicated to open higher on Tuesday morning after Monday's gains. With the market having recovered so much in 2019, investors have to be considering how they want their ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Alector, Bed Bath & Beyond, Dillard’s, Foot Locker, Hasbro, Kraft Heinz, Vale, Xilinx, Zoetis and More

Stocks were indicated to open marginally higher on Monday after solid gains on Friday. Investors are still dealing with mixed news reports, trade policies, politics and the slightly less robust ...
Read Full Story »

Is Immunogen Done After This Ovarian Cancer Study?

ImmunoGen Inc. (NASDAQ: IMGN) shares were halved on Friday after the firm reported late-stage results from its ovarian cancer study. Specifically, the results from its Phase 3 Forward 1 trial ...
Read Full Story »

Jefferies Out With 5 Biotech Stocks Under $10 With Gigantic Upside Potential

While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they ...
Read Full Story »

Why ImmunoGen Could See Another 60% of Potential Upside

ImmunoGen Inc. (NASDAQ: IMGN) shares benefited after the company presented data from its FORWARD II assessment of mirvetuximab soravtansine in combination with pembrolizumab at the Society of Gynecologic Oncology annual meeting. ...
Read Full Story »

Even More Biopharma Catalysts Coming Through the End of March

Biotech and pharmaceutical companies are generally involved in the lengthy process of getting their drug candidates to market through clinical trials. The amount of risk involved ranges from fair to ...
Read Full Story »

Major Biopharma Catalysts and FDA Events to Look For in March

Companies in the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval. But with ...
Read Full Story »

Top Analyst Upgrades and Downgrades: AK Steel, Apple, Biogen, EA, FitBit, Foot Locker, McDonald’s, Pfizer and More

Stocks have proven that they can sell off when they want to again, but the reality is that the markets were barely 2% off of last week's all-time highs. And ...
Read Full Story »

ImmunoGen Shares Collapse After Huge Miss on Profits, Revenues

ImmunoGen Inc. (NASDAQ: IMGN) reported third-quarter 2017 earnings before markets opened Thursday. The biotech company posted a net loss per share of $0.61 on operating revenues of $8.5 million. In ...
Read Full Story »

Why ImmunoGen’s Secondary Makes Sense

ImmunoGen Inc. (NASDAQ: IMGN) saw its shares make a sharp turn downward early Thursday morning after the stock has seen an incredible year of trading so far. Shares taking a ...
Read Full Story »

ImmunoGen Riding High on Jazz Pharma Deal

ImmunoGen Inc. (NASDAQ: IMGN) announced this week that it has decided to partner with Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) for the development and commercialization of two early-stage, hematology-related antibody-drug conjugate ...
Read Full Story »

ImmunoGen and Jazz Enter Into Global Collaboration

ImmunoGen Inc. (NASDAQ: IMGN) has decided to partner with Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) for the development and commercialization of two early-stage, hematology-related antibody-drug conjugate (ADC) programs, as well as ...
Read Full Story »

Top Analyst Upgrades and Downgrades: AutoZone, O’Reilly Automotive, Immunogen, Medtronic, Nike, OncoSec, Schlumberger and More

Stocks were indicated to open lower on Thursday, a day after the Nasdaq regained lost footing when the Dow and S&P 500 turned in mixed results. This bull market is ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Amarin, Amex, Barrick Gold, Cameco, Groupon, ImmunoGen, JPMorgan, Whole Foods and More

Stocks were indicated to open marginally higher on Thursday after a solid rally on Wednesday. Even though this bull market is well over eight years old, equity investors keep finding ...
Read Full Story »